Ärzteblatt Sachsen 3|2021
Literatur
[1] Berlin DA, Gulick RM,Martinez FJ: Severe COVID-19. The New England journal of medicine 2020; 383:2451-2460
[2] Wu JT, Leung K, Bushman M, et al: Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat. Med. 2020; 26:506-510
[3] Covino M, De Matteis G, Santoro M, et al: Clinical characteristics and prognostic factors in COVID-19 patients aged ≥80years. Geriatr Gerontol Int 2020; 20:704-708
[4] Tobin MJ, Laghi F,Jubran A: Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. Am. J. Respir. Crit.
Care Med. 2020; 202:356-360
[5] Butt I, Sawlani V,Geberhiwot T: Prolonged confusional state as first manifestation of COVID-19.
Ann Clin Transl Neurol 2020; 7:1450-1452
[6] Beach SR, Praschan NC, Hogan C, et al: Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. Gen. Hosp. Psychiatry 2020; 65:47-53
[7] Kennedy M, Helfand BKI, Gou RY, et al: Delirium in Older Patients With COVID-19 Presenting to the Emergency Department. JAMA Netw Open 2020; 3:e2029540
[8] Zazzara MB, Penfold RS, Roberts AL, et al: Probable delirium is a presenting symptom of COVID-19 in frail, older adults: a cohort study of 322 hospitalised and 535 community-based older adults. Age Ageing 2020
[9] Helms J, Kremer S, Merdji H, et al: Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients.
Crit Care 2020; 24:491
[10] Mohammadi S, Moosaie F,Aarabi MH: Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV-2 and Potential Immunological Mechanisms. Mol Neurobiol 2020; 57:5263-5275
[11] Kotfis K, Williams Roberson S, Wilson JE, et al: COVID-19: ICU delirium management during SARS-CoV-2 pandemic.
Crit Care 2020; 24:176
[12] Mao L, Jin H, Wang M, et al: Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020; 77:683-690
[13] Nalleballe K, Reddy Onteddu S, Sharma R, et al: Spectrum of neuropsychiatric manifestations in COVID-19. Brain.
Behav. Immun. 2020; 88:71-74
[14] Pandharipande PP, Girard TD, Jackson JC, et al: Long-term cognitive impairment after critical illness.
The New England journal of medicine 2013; 369:1306-1316
[15] Haussmann R, Bauer M,Donix M: [Non-withdrawal-related delirium : Evidence on prevention and therapy].
Das nichtentzugsbedingte Delir : Evidenz zu Pravention und Therapie. Der Nervenarzt 2016; 87:534-542 [16] Meagher D, Adamis D, Timmons S, et al: Developing a guidance resource for managing delirium in patients with
COVID-19. Ir J Psychol Med 2020; 1-6
[17] Baller EB, Hogan CS, Fusunyan MA, et al: NeurocOVID: Pharmacological Recommendations for Delirium Associated With COVID-19. Psychosomatics 2020; 61:585-596
[18] LaHue SC, James TC, Newman JC, et al: Collaborative Delirium Prevention in the Age of COVID-19. J. Am. Geriatr.
Soc. 2020; 68:947-949
[19] Inouye SK, Westendorp RGJ,Saczynski JS: Delirium in elderly people. Lancet (London, England) 2014; 383:911-922 [20] Lonergan E, Britton AM, Luxenberg J, et al: Antipsychotics for delirium. Cochrane Database Syst Rev 2007; CD005594 [21] Zhang R, Wang X, Ni L, et al: COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020; 250:117583 [22] Lonergan E, Luxenberg J, Areosa Sastre A, et al: Benzodiazepines for delirium. Cochrane Database Syst Rev 2009;
CD006379
